Poet: William Carlos Williams
Poem: The Crowd At The Ball Game
Poem of the Day:
Mar 18 2008
Comment 15 of 15, added on July 18th, 2014 at 2:47 PM.
CEkoQT This is one awesome post.Really looking forward to read more. Will read on...
Comment 14 of 15, added on May 26th, 2013 at 9:26 AM.
NASCAR drivers recall Dick Trickle as unique and fun - USA Today
STOCKHOLM, Sweden, May 17 (UPI) -- In utero exposure to depression medications may increase the risk of autism spectrum disorders in less than 1 percent of cases, researchers in Sweden say.
First author Dheeraj Rai, a clinical lecturer at the Department of Public Health Sciences at Karolinska Institutet in Stockholm, and colleagues at the University of Bristol; Avon and Wiltshire Partnership Mental Health NHS Trust in Bristol, England; and Drexel University School of Public Health on Philadelphia said the study involved 4,429 cases of autism spectrum disorder -- 1,828 with and 2,601 without intellectual disability and 43,277 age and sex matched controls.
The study involved 1,679 cases of autism spectrum disorder and 16,845 controls with data on maternal anti-depressant use.
The study, published in the British Medical Journal, said parental depression and other characteristics were recorded in administrative registers before the birth of the child. Maternal anti-depressant use, recorded at the first antenatal interview, was available for children born from 1995 onwards.
A history of maternal -- but not paternal -- depression was associated with an increased risk of autism spectrum disorders in offspring, the study said. In the subsample with available data on drugs, this association was confined to women reporting anti-depressant use during pregnancy irrespective of whether selective serotonin reuptake inhibitors or non-selective monoamine reuptake inhibitors were reported, the study said.
"Whether this association is causal or reflects the risk of autism with severe depression during pregnancy requires further research," the study authors wrote in the study. "However, assuming causality, anti-depressant use during pregnancy is unlikely to have contributed significantly towards the dramatic increase in observed prevalence of autism spectrum disorders as it explained less than 1 percent of cases."
Comment 13 of 15, added on May 26th, 2013 at 2:37 AM.
Keegan Bradley has 3-stroke lead at Nelson - USA Today
The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.
Prostate cancer forms in a gland in the male reproductive system found below the bladder and in front of the rectum. The male sex hormone testosterone stimulates the prostate tumors to grow. According to the National Cancer Institute, an estimated 238,590 men will be diagnosed with prostate cancer and 29,720 will die from the disease in 2013.
Xofigo is being approved more than three months ahead of the product¡¯s prescription drug user fee goal date of Aug. 14, 2013, the date the agency was scheduled to complete review of the drug application. The FDA reviewed Xofigo under the agency¡¯s priority review program, which provides for an expedited review of drugs that appear to provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products.
¡°Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues,¡± said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA¡¯s Center for Drug Evaluation and Research. ¡°Xofigo is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer.¡±
In August 2012, the FDA approved Xtandi to treat men with metastatic castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone. Xtandi is approved for patients who have previously been treated the chemotherapy drug docetaxel.
Xofigo¡¯s safety and effectiveness were evaluated in a single clinical trial of 809 men with symptomatic castration-resistant prostate cancer that spread to bones but not to other organs. Patients were randomly assigned to receive Xofigo or a placebo plus best standard of care.
The study was designed to measure overall survival. Results from a pre-planned interim analysis showed men receiving Xofigo lived a median of 14 months compared to a median of 11.2 months for men receiving placebo. An exploratory updated analysis conducted later in the trial confirmed Xofigo¡¯s ability to extend overall survival.
The most common side effects reported during clinical trials in men receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg, ankle or foot. The most common abnormalities detected during blood testing included low levels of red blood cells (anemia), lymphocytes (lymphocytopenia), white blood cells (leukopenia), platelets (thrombocytopenia) and infection-fighting white blood cells (neutropenia).
Are you looking for more information on this poem? Perhaps you are trying to analyze it? The poem, The Crowd At The Ball Game, has received 15 comments. Click here to read them, and perhaps post a comment of your own.